[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Samsung Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":610},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,119,0,25,[9,53,77,98,124,147,168,202,222,239,261,283,313,339,360,382,403,430,452,478,499,521,544,570,589],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100651110","digital-therapeutics-for-social-cognitive-function-in-schizophrenia-spectrum-disorder-a-randomized-controlled-trial-100651110",false,"NCT07755605","Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder","A Prospective, Randomized Parallel, Single Institution, Researcher-led Clinical Trial on the Effect of Improving Social Cognitive Function by Using Digital Therapy Devices in Patients With Schizophrenia Spectrum Disorder","A. Inclusion Criteria\n\nParticipants must meet all of the following criteria:\n\n1. Adults aged 19 to 60 years.\n2. Meet the diagnostic criteria for schizophrenia or schizoaffective disorder according to DSM-5 and ICD-11.\n3. Have completed at least a middle school education.\n4. Be able to read and write in Korean.\n5. Be able to use a smartphone application independently.\n6. Provide written informed consent before participation.\n7. Receiving stable antipsychotic treatment (dose variation ≤30%) for at least 3 months before enrollment.\n\nExclusion Criteria\n\n1. Current or past diagnosis of intellectual disability.\n2. Initiation of or current participation in structured psychosocial interventions (e.g., cognitive behavioral therapy or social cognition training) within the past 3 months.\n3. Considered by the investigator to be at significant risk of suicide. 4, Pregnant or having a positive pregnancy test at screening.\n\n5\\. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data interpretation.","ALL","19 Years","60 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue perception, in individuals with schizophrenia spectrum disorders.\n\nIn this randomized controlled trial, participants will be assigned either to use AffectUs for 10 weeks in addition to treatment as usual or to receive psychoeducational materials and treatment as usual. Participants will complete assessments at baseline, week 5, week 10, and week 15 to evaluate social cognition, clinical outcomes, and safety.",[28,29],"Schizophrenia","Schizoaffecitve Disorder",[31,32,33,34,35,36,37,38,39],"Schizophrenia Spectrum Disorder","Social Cognition","Emotion Recognition","Digital Therapeutics","Psychosocial Rehabilitation","AffectUs","Social Cue Perception","Emotion Processing","Mobile Application","RECRUITING","2026-08-19",{"date":43,"type":44},"2026-08-21","ACTUAL",{"date":46,"type":44},"2026-07-15",{"date":48,"type":22},"2027-03",{"name":50,"class":51},"Samsung Medical Center","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":52},"100652650","phase-4-clinical-impact-of-sglt2-inhibitor-after-dc-cardioversion-in-persistent-af-with-hfpef-100652650","NCT07776054","Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF","Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥19 years\n* Persistent atrial fibrillation\n* H2FPEF score ≥6 or HFA-PEFF score ≥5\n* Restoration of sinus rhythm after electrical cardioversion\n\nExclusion Criteria:\n\n* Previous use of an SGLT2 inhibitor\n* Intracardiac thrombus on transesophageal echocardiography\n* Refusal to participate",{"count":61,"type":22},200,[63],"PHASE4","SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.",[66,67,68],"Atrial Fibrillation","SGLT2 Inhibitor","DC Cardioversion","2026-08-17",{"date":71,"type":44},"2026-08-20",{"date":73,"type":44},"2024-02-01",{"date":75,"type":22},"2027-09-01",{"name":50,"class":51},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":52},"100652299","phase-2-a-randomized-study-to-evaluate-the-efficacy-of-a-reduced-starting-dose-of-lazertinib-leclaza-and-preemtive-magnesium-supplementation-to-prevent-lazertinibleclaza-induced-peripheral-neuropathy-100652299","NCT07774520","A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy","A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemptive Magnesium Supplementation to Prevent Lazertinib (Leclaza)-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n1. Pathologically diagnosed pulmonary adenocarcinoma.\n2. Patient with a stage not amenable to curative treatment by surgery or radiotherapy and requiring palliative chemotherapy.\n3. Patient with no prior treatment history for lung cancer, or who relapsed \\>=6 months after curative-intent therapy (concurrent chemoradiotherapy or adjuvant chemotherapy) with no subsequent anticancer treatment - i.e., a candidate for first-line chemotherapy.\n4. Patient with a confirmed EGFR mutation of Exon 19 deletion or L858R.\n5. Patient able to decide on participation in this study through voluntary decision-making.\n6. Age 19 years or more.\n7. ECOG PS 0-2.\n8. Minimum life expectancy 12 weeks or more.\n9. Adequate organ function.\n\nExclusion Criteria:\n\n* Subjects with confirmed leptomeningeal\u002FCNS metastasis on brain MRI or cerebrospinal fluid examination.\n* Subjects with pre-existing peripheral neuropathy.\n* Subjects who are taking any agent that may affect the development of peripheral neuropathy for reasons other than peripheral neuropathy (magnesium, pregabalin, gabapentin, duloxetine) and refuse to discontinue its use.\n* Subjects for whom, in the physician's judgment, participation in this study would carry greater harm than benefit (no specific items specified).\n* Uncontrolled systemic disease, including uncontrolled hypertension, severe heart failure, active bleeding, or active infection.\n* Pregnant or breastfeeding women.\n* History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or evidence of clinically active ILD.\n* QTc prolongation based on QTc measured by ECG during the screening period (QTc \\>=470 msec).\n* Subjects with a history of hypersensitivity to Magnes tablet.\n* Subjects with hereditary disorders of sugar metabolism such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Subjects with a history of severe symptomatic renal failure.\n* Subjects taking a drug expected to have a clinically significant interaction when co-administered with magnesium-containing preparations - such as phosphate preparations, calcium preparations, oral tetracyclines, antacids, or levodopa - for whom discontinuation or substitution of the drug is not possible.",{"count":85,"type":22},1173,[87],"PHASE2","Lazertinib is currently approved as a first-line treatment for EGFR-mutant NSCLC in South Korea. However, many patients experience peripheral neuropathy, which causes severe numbness, tingling, or painful muscle cramps. This side effect significantly lowers patients' quality of life and often leads to treatment interruptions. This phase 2, open-label, randomized clinical trial newly diagnosed EGFR mutant NSCLC patients is based on the hypothesis that a lower dose of lazertinib combined with magnesium supplementation will result in a more tolerable safety profile without compromising efficacy outcomes",[90,91],"Non-small Cell Lung Cancer(NSCLC)","EGFR Mutant",{"date":41,"type":44},{"date":94,"type":44},"2026-05-26",{"date":96,"type":22},"2029-12-31",{"name":50,"class":51},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":52},"100652506","effect-of-mechanical-power-based-lung-protective-ventilation-during-one-lung-ventilation-100652506","NCT07772804","Effect of Mechanical Power-based Lung-protective Ventilation During One-lung Ventilation","Incidence of Postoperative Pulmonary Complications Between Mechanical Power-based Versus Conventional Lung Protective Ventilation During One-lung Ventilation: a Randomized Controlled Trial","Inclusion Criteria\n\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Elective thoracic surgery requiring lung lobectomy under one-lung ventilation\n* Age 18 years or older\n* Written informed consent obtained from the patient\n\nExclusion Criteria\n\n* Prior history of thoracic surgery\n* Emergency surgery\n* Pregnancy or lactation\n* Known contraindication to one-lung ventilation\n* Inability to provide informed consent or cooperate with the study protocol",{"count":106,"type":22},164,[25],"The goal of this clinical trial is to determine whether a mechanical power-based lung-protective ventilation strategy during one-lung ventilation reduces the incidence of postoperative pulmonary complications in adult patients undergoing lung resection surgery.\n\nMechanical power during pressure-regulated volume control mode is calculated using the formula below.\n\nMechanical power (J\u002Fmin) = 0.098 x respiratory rate x tidal volume x (inspiratory airway pressure above positive end-expiratory pressure + positive end-expiratory pressure)\n\nThe main questions it aims to answer are:\n\n* Does a mechanical power-based lung-protective ventilation strategy significantly lower the incidence of major postoperative pulmonary complications compared to conventional ventilation?\n* How does this strategy impact intraoperative hemodynamic and vital profiles (e.g., blood pressure, cardiac output, vasopressor requirements, and blood oxygen saturation) during one-lung ventilation?\n\nParticipants will:\n\n* Be randomized to receive either a mechanical power-based lung-protective ventilation strategy or a conventional lung-protective ventilation strategy exclusively during one-lung ventilation.\n* Be closely monitored for the occurrence of major postoperative pulmonary complications (atelectasis, pneumonia, acute respiratory distress syndrome, and pulmonary aspiration) and adverse events for 1 month postoperatively.",[110,111],"Lung Cancer (Diagnosis)","Pulmonary Complications in Surgical Patients",[113,114,115],"mechanical power","lung protective ventilation","postoperative pulmonary complication","NOT_YET_RECRUITING","2026-08-14",{"date":41,"type":44},{"date":120,"type":22},"2026-08-30",{"date":122,"type":22},"2027-09-30",{"name":50,"class":51},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100261924","the-molecular-screening-study-for-the-umbrella-trial-sukses-in-relapsed-small-cell-lung-cancer-patients-sukses-s-100261924","NCT02688894","The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]","Inclusion Criteria:\n\n1. Provision of fully informed consent prior to any study specific procedures.\n2. Patients must be ≥20 years of age.\n3. Histologically or cytologically confirmed Small cell lung cancers\n4. ECOG performance status of 0 to 2\n5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment\n6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis\n\nExclusion Criteria:\n\n1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer\n2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)\n3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.","20 Years",{"count":132,"type":22},797,"OBSERVATIONAL","This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.\n\nThis procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and\u002For blood.\n\nImmunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.\n\nTumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and\u002For FISH.\n\nSpecific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.",[136,137],"Small Cell Lung Cancers","Neuroendocrine Carcinoma","2026-08-10",{"date":140,"type":44},"2026-08-12",{"date":142,"type":44},"2016-06-10",{"date":144,"type":22},"2028-12",{"name":50,"class":51},6,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100330126","genomic-analysis-to-identify-a-predictive-biomarker-for-immunotherapy-100330126","NCT03578185","Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy","LC_Biomarker","Inclusion Criteria:\n\n1. aged above or equal to 18\n2. Histologically confirmed lung cancer patients\n3. Patient treated with immune checkpoint inhibitor\n\nExculsion Criteria:\n\nNA","18 Years",{"count":156,"type":22},2000,"This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.",[159],"Lung Cancer","2026-08-09",{"date":140,"type":44},{"date":163,"type":44},"2018-04-11",{"date":165,"type":22},"2030-12-31",{"name":50,"class":51},3,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":176,"minAge":177,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":52},"100651298","phase-3-partial-breast-irradiation-without-sentinel-lymph-node-biopsy-in-low-risk-early-breast-cancer-100651298","NCT07757958","Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer","A Phase III Randomized Trial of Partial Versus Whole Breast Radiotherapy in Clinically Node-Negative Early Breast Cancer Omitting Sentinel Lymph Node Biopsy (APROOB Trial)","APROOB","Inclusion Criteria:\n\n* Female ≥40 years with histologically confirmed unilateral invasive breast cancer.\n* No suspicious nodal metastasis on preoperative axillary ultrasound (cN0).\n* Single lesion in the affected breast on preoperative breast ultrasound and mammography.\n* Treated with breast-conserving surgery with pathologically negative margins for the invasive tumor.\n* Sentinel lymph node biopsy not performed at surgery (pNx).\n* Maximum diameter of invasive tumor ≤2 cm on final pathology (pT1).\n* Histologic grade 1 or 2.\n* Signed informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* History of malignancy other than breast cancer within 5 years (except adequately treated non-melanoma skin cancer, or carcinoma in situ excluding breast carcinoma in situ).\n* Preoperative diagnosis of carcinoma in situ without axillary nodal sampling, subsequently diagnosed as invasive breast cancer on final pathology with SLNB omitted.\n* Lymphovascular invasion present (LVI+).\n* Multifocal or multicentric tumor in the same breast confirmed radiologically or pathologically.\n* Bilateral or inflammatory breast cancer.\n* Prior radiotherapy to the breast or thorax.\n* Confirmed pathogenic or likely pathogenic variant in a hereditary breast cancer gene (including BRCA1\u002F2).\n* Recurrent breast cancer.","FEMALE","40 Years",{"count":179,"type":22},520,[181],"PHASE3","This is a multicenter, randomized, phase III non-inferiority trial in women aged 40 years or older with clinically node-negative (cN0), pathologically pT1 (≤2 cm), grade 1-2, lymphovascular invasion (LVI)-negative invasive breast cancer treated with breast-conserving surgery (BCS) in whom sentinel lymph node biopsy (SLNB) was omitted (pNx). Eligible patients are randomized 1:1 to partial breast irradiation (PBI) or whole breast irradiation (WBI). The primary aim is to determine whether PBI is non-inferior to WBI with respect to the 5-year recurrence-free survival (RFS) rate. Secondary aims include comparison of axillary recurrence, overall survival, locoregional recurrence, treatment-related toxicity, and quality of life between arms.",[184,185,186],"Breast Cancer","Node-negative Breast Cancer","Early-Stage Invasive Breast Carcinoma",[188,189,190,191,192,193],"Partial breast irradiation","Whole breast irradiation","Breast-conserving surgery","Sentinel lymph node biopsy omission","Node-negative","Radiotherapy de-escalation","2026-08-06",{"date":196,"type":44},"2026-08-11",{"date":198,"type":22},"2026-08-01",{"date":200,"type":22},"2036-06",{"name":50,"class":51},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":52},"100650802","net-clinical-benefit-of-edoxaban-versus-apixaban-in-patients-with-atrial-fibrillation-and-coronary-artery-disease-100650802","NCT07753200","Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease","SMARTDECISION3","Inclusion Criteria:\n\n* Patients must be at least 19 years of age\n* Patients with AF requiring oral anticoagulation therapy (CHA2DS2-VaSc 2 or more)\n* Documented coronary artery disease, defined as at least one of the following: history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG), major epicardial coronary artery stenosis ≥50% on coronary computed tomography angiography (CCTA) or invasive coronary angiography\n* Patients who can understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindications to study medications (apixaban or edoxaban)\n* Severe renal impairment (creatinine clearance \\\u003C15 mL\u002Fmin) or dialysis\n* Active major bleeding\n* Indication requiring alternative anticoagulation (e.g., mechanical valve surgery or moderate \u002F severe mitral stenosis)\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Pregnant or lactating women",{"count":210,"type":22},3000,[63],"Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.",[214,215],"Atrial Fibrillation (AF)","Coronary Arterial Disease (CAD)",{"date":138,"type":44},{"date":218,"type":44},"2026-07-20",{"date":220,"type":22},"2031-12-31",{"name":50,"class":51},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":176,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":52},"100507943","prospective-cohort-for-tumor-bed-boost-radiotherapy-in-her2-positive-breast-cancer-100507943","NCT05893966","Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer","BOOST-HER2","Inclusion Criteria:\n\n* Female patients with age minimum 19\n* Pathological confirmation of HER2+ invasive breast cancer\n* Eastern Cooperative Oncology Group performance status 0-2\n* Informed consent of the participant\n\nExclusion Criteria:\n\n* Pathological confirmation of ductal carcinoma in situ of the breast\n* Previous history of radiation therapy to ipsilateral breast",{"count":230,"type":22},400,"The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.\n\nThe main questions it aims to answer are:\n\n* 7-year ipsilateral breast tumor recurrence\n* 7-year disease-free survival\n* 7-year locoregional recurrence\n* 7-year overall survival\n* Adverse events of radiation therapy\n\nParticipants will be assessed by multi-dimensional methods after radiation therapy:\n\n* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination\n* Assessment for the adverse events according to CTCAE version 5.0",[184],{"date":138,"type":44},{"date":235,"type":44},"2022-11-29",{"date":237,"type":22},"2032-11-29",{"name":50,"class":51},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":247,"studyType":133,"phases":4,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":52},"100620626","prospective-cohort-study-of-bachmann-bundle-versus-right-atrial-appendage-pacing-impact-on-atrial-cardiomyopathy-evaluated-by-echocardiographic-parameters-and-clinical-outcome-100620626","NCT07360067","Prospective Cohort Study of Bachmann Bundle Versus Right Atrial Appendage Pacing: Impact on Atrial Cardiomyopathy Evaluated by Echocardiographic Parameters and Clinical Outcome","BRAVE","Inclusion Criteria:\n\n* Patients aged 19 years or older\n* Patients diagnosed with sick sinus syndrome who are scheduled for de novo implantation of a permanent pacemaker or permanent implantable cardioverter-defibrillator\n* Patients or their legal representatives who voluntarily consent to the access of medical records and study data throughout the entire research period\n\nExclusion Criteria:\n\n* Patients with persistent or permanent AF\n* Patients with a life expectancy of less than one year due to other comorbidities\n* Pregnant or breastfeeding women\n* Patients who refuse active treatment",{"count":61,"type":22},"1 Year","The goal of this observational study is to evaluate the impact of different atrial pacing sites-Bachmann's bundle pacing versus right atrial appendage pacing-on the development and progression of atrial cardiomyopathy in patients diagnosed with sick sinus syndrome who are undergoing permanent pacemaker implantation.",[250],"Sick Sinus Syndrome",[252],"bachmann bundle pacing","2026-07-25",{"date":255,"type":44},"2026-07-28",{"date":257,"type":44},"2025-12-09",{"date":259,"type":22},"2028-12-31",{"name":50,"class":51},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":282},"100648832","empirical-anatomy-based-ablation-vs-emphasize-map-guided-substrate-ablation-in-persistent-atrial-fibrillation--compass-af-100648832","NCT07726901","Empirical Anatomy-Based Ablation vs Emphasize Map-Guided Substrate Ablation in Persistent Atrial Fibrillation : (COMPASS-AF)","COMPASS-AF","Inclusion Criteria:\n\n* Adults aged 19 years or older who have voluntarily provided written informed consent to participate in the study\n* Patients diagnosed with persistent atrial fibrillation (AF) who are scheduled to undergo catheter ablation for AF.\n\nExclusion Criteria:\n\n* History of prior catheter ablation or MAZE surgery for atrial fibrillation.\n* Left atrial (LA) diameter exceeding 60 mm.\n* Patients with end-stage renal disease (ESRD).\n* History of prior open-heart surgery.\n* Women who are pregnant, lactating, or of childbearing potential.\n* Heart failure corresponding to New York Heart Association (NYHA) functional class IV.\n* Acute coronary syndrome (ACS) experienced within the past 3 months.\n* Patients with terminal illness and a life expectancy of less than one year.\n* Any other condition that the investigator deems inappropriate for participation in the study.",{"count":269,"type":22},360,[25],"This study is aimed to compare the clinical efficacy of two different catheter ablation strategies in patients with persistent atrial fibrillation.\n\nParticipants will be randomized 1:1 into either the Anatomy-based group or the Emphasize map-guided group\n\n* Anatomy-based group : Pulmonary vein isolation (PVI) using pulsed-field ablation (PFA) with a single-shot multielectrode catheter.\n* Emphasize map-guided group : PVI using radiofrequency (RF) ablation followed by additional EnSite X-guided pathologic substrate modification.\n\nParticipants will be followed for 1 year to compare the incidence of any atrial tachyarrhythmia and other clinical parameters between the two groups.",[214],[274],"Emphasize map","2026-07-21",{"date":277,"type":44},"2026-07-24",{"date":279,"type":44},"2026-05-19",{"date":165,"type":22},{"name":50,"class":51},2,{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":292,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":52},"100646523","phase-2-belvarafenib-for-cns-efficacy-in-patients-with-braf-altered-solid-tumors-100646523","NCT07688356","Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors","An Exploratory Phase 2 Study for Evaluating CNS Efficacy of Belvarafenib in Patients With BRAF-Altered Solid Tumors","Inclusion Criteria: (Applicable to Both Cohorts)\n\n1. Male or female patients aged 19 years or older.\n2. Histologically confirmed primary brain tumor or metastatic brain tumor.\n3. Documented BRAF mutation, including point mutations (e.g., V600E) or BRAF fusion mutations.\n4. Willing and able to provide written informed consent prior to participation in the study.\n5. Estimated life expectancy of at least 3 months.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n7. Adequate organ function demonstrated by laboratory assessments performed within 14 days prior to the first dose of study treatment, meeting all of the following criteria:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL\n   * Hemoglobin ≥ 9 g\u002FdL\n   * Platelet count ≥ 100 × 10⁹\u002FL\n   * PT\u002FINR and aPTT ≤ 1.5 × upper limit of normal (ULN)\n   * Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for patients with Gilbert syndrome)\n   * AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN in patients with liver metastases)\n   * Alkaline phosphatase ≤ 2.5 × ULN (≤ 5 × ULN in patients with liver or bone metastases)\n   * Albumin ≥ 2.5 g\u002FdL\n   * Amylase ≤ 1.5 × ULN\n   * Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance (CrCl) \\> 50 mL\u002Fmin using the Cockcroft-Gault formula\n8. Women of childbearing potential (defined as women from menarche until 1 year after menopause unless permanently sterile) and men with partners of childbearing potential must agree to use highly effective contraception throughout the study and for 3 months after the last dose of Belvarafenib.\n\n   Women of childbearing potential must have a negative pregnancy test during screening unless surgically sterile.\n\n   Acceptable contraceptive methods include:\n   * Hormonal contraception\n   * Intrauterine device (IUD) or intrauterine system (IUS)\n   * Vasectomy or bilateral tubal occlusion\n   * Complete abstinence Barrier methods (e.g., male or female condoms); if barrier methods are used alone, the use of two complementary barrier methods is recommended.\n9. Additional Inclusion Criteria for Cohort 1 (Primary Brain Tumors) 1) Patients with BRAF-mutant primary brain tumors who meet at least one of the following conditions:\n\n   \\- No available or appropriate local treatment options (e.g., surgery or radiotherapy);\n   * Radiographic evidence of disease recurrence or progression following standard therapy (including surgery and\u002For chemoradiotherapy \\[CCRT\\]), with no further suitable standard treatment available;\n   * Standard treatment is considered inappropriate or unavailable in the investigator's judgment.\n10. Additional Inclusion Criteria for Cohort 2 (Metastatic Brain Tumors)\n\n\u003C!-- -->\n\n1. Patients with brain metastases from BRAF-mutant solid tumors.\n2. Patients with radiographic evidence of disease progression after receiving the standard treatment for the primary malignancy, or whose disease is refractory to conventional therapy, regardless of prior exposure to BRAF-targeted therapy, and who have no available or appropriate local treatment options (e.g., surgery or radiotherapy).\n3. At least one measurable intracranial lesion, with a maximum of five target lesions, as defined by the Response Assessment in Neuro-Oncology (RANO) criteria.\n\nExclusion Criteria: (Applicable to Both Cohorts)\n\n1. History of hypersensitivity to BRAF inhibitors or related compounds. Prior treatment with a BRAF inhibitor is permitted.\n2. Presence of hematologic malignancy or double primary malignancies at screening. The following second primary malignancies are permitted:\n\n   * Carcinoma in situ of the cervix successfully treated at least 1 year before enrollment;\n   * Papillary thyroid carcinoma treated with curative surgical resection;\n   * Completely resected cutaneous squamous cell carcinoma.\n3. Any of the following:\n\n   \\- Receipt of an investigational medicinal product within 28 days or within five half-lives (whichever is longer) before the first dose of study treatment;\n\n   \\- Major surgery within 28 days before the first dose of study treatment;\n   * Newly initiated or recently increased systemic corticosteroid therapy equivalent to ≥10 mg\u002Fday of prednisolone within 28 days before the first dose.\n   * Patients receiving a stable dose for at least 2 weeks or requiring continued corticosteroid treatment after surgery may be enrolled at the investigator's discretion;\n   * Current treatment with systemic immunosuppressive agents or anticipated need for continuous systemic immunosuppression during the study. Topical preparations, inhaled corticosteroids, ophthalmic preparations, and local injections are permitted;\n   * More than five prior systemic anticancer treatment regimens.\n4. Unresolved adverse events of CTCAE Grade ≥2 from previous anticancer therapy at screening, except alopecia.\n5. Any of the following cardiovascular conditions:\n\n   * Mean QTcF \\>440 msec;\n   * New York Heart Association (NYHA) Class III or IV heart failure;\n   * Cardiac metastasis;\n   * Uncontrolled electrolyte abnormalities (hyponatremia, hypokalemia, hypocalcemia, or hypomagnesemia);\n   * Within 6 months before the first dose: unstable angina, acute coronary syndrome (including myocardial infarction), uncontrolled arrhythmia (except sinus arrhythmia or adequately controlled atrial fibrillation for at least 30 days), symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack;\n   * Coronary angioplasty, coronary\u002Fperipheral artery bypass graft surgery, or coronary stent placement within 6 months before the first dose;\n   * History of congenital long QT syndrome or clinically significant CTCAE Grade ≥2 ventricular or atrial dysrhythmias.\n6. Any of the following ophthalmologic disorders:\n\n   \\- History or evidence at screening of retinal vein occlusion (RVO), central serous retinopathy (CSR), or neovascular macular degeneration;\n\n   \\- Intraocular pressure ≥21 mmHg with glaucoma.\n7. Current or prior interstitial lung disease (ILD), drug-induced ILD, or radiation pneumonitis requiring corticosteroid treatment.\n8. Uncontrolled hypertension.\n9. Uncontrolled infectious or neurologic disease, active infection requiring intravenous antibiotics, known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or active hepatitis C virus (HCV) infection.\n10. Inability to swallow oral tablets or any gastrointestinal condition that may interfere with the administration, absorption, or metabolism of Belvarafenib, including refractory nausea or vomiting, malabsorption syndrome, external biliary shunt, significant small bowel resection, clinically significant gastrointestinal bleeding, acute pancreatitis within 28 days before the first dose, or diverticulitis.\n11. Requirement for continuous treatment with CYP2C8 substrate medications (e.g., amodiaquine) or rifampin.\n12. Known or suspected substance abuse or alcohol abuse.\n13. Psychological, social, geographic, psychiatric, or congenital conditions that, in the investigator's judgment, would interfere with compliance with the study protocol or follow-up.\n14. Pregnant or breastfeeding women, or women of childbearing potential planning to become pregnant during the study.\n15. Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for study treatment.\n16. Additional Exclusion Criteria for Cohort 1 (Primary Brain Tumors) 1) New intracranial lesions identified within 12 weeks after prior brain radiotherapy when radiation necrosis cannot be reliably distinguished from tumor progression.\n17. Additional Exclusion Criteria for Cohort 2 (Metastatic Brain Tumors) 1) Clinically unstable disease due to uncontrolled primary malignancy. 2) Requirement for concurrent systemic anticancer therapy (e.g., chemotherapy, targeted therapy, or other systemic anticancer treatment) for extracranial disease during the study.",{"count":291,"type":22},30,[87],"This is a Phase 2, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Belvarafenib in patients with BRAF-altered primary brain tumors (Cohort 1) and metastatic brain tumors (Cohort 2). Eligible patients are those with a confirmed BRAF alteration identified by next-generation sequencing (NGS).\n\nPatients who meet the eligibility criteria will receive a detailed explanation of the study, including its purpose, procedures, potential benefits, and risks. Only patients who voluntarily provide written informed consent will be enrolled.\n\nAll enrolled patients will receive Belvarafenib monotherapy at a dose of 450 mg twice daily (BID). The study drug will be taken orally within 30 minutes after meals with at least 200 mL of water, preferably at approximately 12-hour intervals each day. One treatment cycle is defined as 28 consecutive days of continuous dosing without a planned treatment break. Patients will receive treatment for six cycles (approximately six months) as the initial treatment period. Treatment may be extended or discontinued earlier at the investigator's discretion based on clinical benefit, disease status, and tolerability.\n\nDuring the study, patients will undergo regular clinical evaluations, including physical examinations, vital sign assessments, laboratory tests, and monitoring for adverse events. Radiologic assessments using MRI and\u002For CT will be performed at scheduled intervals to evaluate tumor response and disease progression. The study aims to determine whether Belvarafenib can control tumor growth, delay disease progression, and improve clinical outcomes in patients with BRAF-altered brain tumors.\n\nIf treatment-related toxicities occur, dose reductions are permitted according to the protocol. The dose may be reduced from 450 mg BID to 300 mg BID, and subsequently to 200 mg BID, if clinically indicated. Temporary treatment interruption may also be implemented until toxicity resolves. If unacceptable toxicity persists despite dose modification, treatment will be permanently discontinued.\n\nStudy treatment may be discontinued if any of the following occurs: confirmed disease progression, unacceptable toxicity, withdrawal of informed consent, inability to comply with the study protocol, receipt of other anticancer therapies that may interfere with study outcomes, or if the investigator determines that continued treatment is no longer in the patient's best interest. However, if radiologic disease progression is observed but the investigator determines that the patient continues to derive clinical benefit, treatment beyond progression may be considered after discussion with the sponsor, with appropriate documentation of the rationale.\n\nAfter discontinuation of study treatment, patients will receive the most appropriate subsequent management, including best supportive care (BSC) or other anticancer therapies, as determined by the treating investigator. Follow-up assessments will continue according to the study protocol.\n\nThe primary objective of this study is to evaluate the efficacy of Belvarafenib in patients with BRAF-altered primary and metastatic brain tumors, while also assessing its safety profile. The results of this study are expected to provide important clinical evidence supporting the development of new treatment strategies for patients with BRAF-altered brain tumors.",[295,296],"Primary Brain Tumor","Metastatic Brain Tumor",[298,299,300,301,302,303,304,305],"Belvarafenib","Pan-RAF inhibitor","BRAF alteration","Primary brain tumor","Brain metastases","Central nervous system","Targeted therapy","Precision oncology","2026-07-06",{"date":308,"type":44},"2026-07-08",{"date":310,"type":44},"2026-06-15",{"date":96,"type":22},{"name":50,"class":51},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":338,"locationsCount":52},"100628866","phase-3-routine-use-of-potassium-competitive-acid-blocker-vs-guideline-directed-gastrointestinal-protection-strategy-in-acute-myocardial-infarction-100628866","NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial","PCAB-AMI","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).\n* Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.\n\nExclusion Criteria:\n\n* History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \\[P-CAB\\] or proton pump inhibitor \\[PPI\\]).\n* Presence of active gastrointestinal bleeding.\n* Pregnant or breastfeeding women.\n* Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).\n* Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.",{"count":322,"type":22},5000,[181],"This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).",[326,327],"Acute Myocardial Infarction (AMI)","Gastrointestinal Bleeding",[329,330,331,332],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","Potassium Competitive Acid Blocker","Zastaprazan","2026-06-23",{"date":335,"type":44},"2026-06-26",{"date":333,"type":44},{"date":165,"type":22},{"name":50,"class":51},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":4},"100642568","livalozet-versus-high-intensity-statin-in-older-patients-with-coronary-artery-disease-undergoing-percutaneous-coronary-intervention-100642568","NCT07626840","Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","Pitavastatin With Ezetimibe Combination Therapy Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","SMARTDECISION2","Inclusion Criteria\n\n* Age 75 years or older\n* Patients diagnosed with stable coronary artery disease or acute coronary syndrome and requiring coronary artery intervention due to coronary artery stenosis\n* Patients with primary hypercholesterolemia and mixed dyslipidemia\n* Patients who understand the risks and benefits of treatment, as well as alternatives, and can voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with hypersensitivity or contraindications to statins or ezetimibe\n* Patients with active liver disease or persistently elevated AST or ALT levels exceeding three times the upper limit of normal\n* Patients with a history of organ transplantation (kidney, liver, etc.)\n* Pregnant or lactating women\n* Patients with a life expectancy of less than one year due to non-cardiac disease, or those deemed unable to participate in the study and follow-up (based on the medical judgment of the investigator at each site)","75 Years",{"count":322,"type":22},[25],"Acute myocardial infarction is one of the leading causes of death in elderly patients, and the importance of lipid-lowering therapy as a secondary prevention strategy to reduce cardiovascular events is emphasized. The European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines recommend lowering low-density lipoprotein-cholesterol (LDL-C) below 55 mg\u002FdL or by at least 50% from baseline as a treatment goal and recommend high-intensity statin therapy (Atorvastatin 40-80 mg, Rosuvastatin 20 mg). Statins have been shown to reduce cardiovascular risk in elderly patients as well. However, these patients exhibit a higher rate of statin intolerance due to side effects associated with high-intensity statins, such as myalgia, hepatotoxicity, cognitive decline, and increased risk of diabetes. Consequently, dose reduction or discontinuation is required more frequently compared to younger patients. Therefore, establishing an appropriate lipid-lowering strategy for elderly patients is necessary, considering not only efficacy but also drug tolerability. Consequently, in elderly patients, reducing the statin intensity from the outset and considering combination therapy with drugs having different mechanisms of action, such as ezetimibe, may be warranted. Pitavastatin is classified as a moderate-intensity statin. Previous studies have confirmed that Pitavastatin demonstrates non-inferior efficacy compared to Rosuvastatin and Atorvastatin. Several observational studies report that Pitavastatin has fewer drug interactions than other statins and lower rates of diabetes onset and elevated liver enzymes. Therefore, Pitavastatin may be an appropriate choice for moderate-intensity statin therapy in elderly patients. Thus, this study aims to evaluate whether combination therapy with Pitavastatin and Ezetimibe (Livalozet 4\u002F10mg) after coronary intervention in patients aged 75 years or older with coronary artery disease is non-inferior to high-intensity statin therapy (Atorvastatin 40-80 mg or Rosuvastatin 20 mg). If this study demonstrates that moderate-intensity statin therapy combined with ezetimibe is non-inferior to high-intensity statin therapy while also having fewer adverse effects, it could provide evidence for an effective and safe cholesterol treatment option for elderly patients.",[352],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","2026-06-08",{"date":355,"type":44},"2026-06-10",{"date":357,"type":22},"2026-06-01",{"date":220,"type":22},{"name":50,"class":51},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":52},"100643149","oxiris-in-septic-aki-100643149","NCT07641660","Oxiris in Septic AKI","Impact of Oxiris on Endothelial Cell Dysfunction and Renal Recovery in Patients With Septic Acute Kidney Injury","Inclusion Criteria:\n\n* Adult patients with AKI, aged ≥ 19 years old\n* Relevant disease states: sepsis-associated AKI\n\nExclusion Criteria:\n\n* Age \\> 85 years old\n* Uncontrolled malignancy\n* End-stage kidney disease\n* End-stage hepatic failure requiring MARS or liver transplantation\n* End-stage heart failure requiring extracorporeal membrane oxygenation (ECMO), left ventricular assist device (LVAD), intra-aortic balloon pump (IABP), or heart transplantation","84 Years",{"count":369,"type":22},32,[25],"Sepsis is a leading cause of acute kidney injury (AKI) in critically ill patients, with sepsis-associated AKI accounting for approximately 50% of all AKI cases in the intensive care unit. The pathophysiology of septic AKI involves a complex interplay of inflammation, endothelial dysfunction, and microvascular injury, leading to impaired renal perfusion and tubular damage. Despite advances in critical care, septic AKI remains associated with high mortality rates and significant risk of progression to chronic kidney disease.\n\nContinuous renal replacement therapy (CRRT) is the standard extracorporeal treatment for AKI in hemodynamically unstable patients. The Oxiris hemofilter (Baxter\u002FVantive) is a specialized AN69-based membrane with enhanced adsorptive capacity for cytokines and endotoxins due to a polyethyleneimine surface treatment and heparin grafting. While Oxiris has demonstrated the ability to reduce circulating inflammatory mediators in septic patients, its impact on endothelial cell dysfunction and subsequent renal recovery has not been systematically evaluated.\n\nThis is a single-center, prospective, open-label, exploratory randomized controlled trial comparing CRRT using the Oxiris filter versus CRRT using a standard filter in patients with sepsis-associated AKI at Samsung Medical Center, Seoul, Korea. A total of 30 patients (15 per group) will be enrolled and allocated using stratified randomization based on SOFA score, baseline renal function, and presence of septic shock.\n\nEligible participants are adult patients (aged 19 years or older) diagnosed with sepsis according to Sepsis-3 criteria who develop AKI (KDIGO stage 2 or higher) requiring CRRT initiation. Key exclusion criteria include end-stage kidney disease, expected survival of less than 24 hours, prior CRRT within 72 hours, and contraindications to heparin-based anticoagulation. CRRT will be maintained for a minimum of 72 hours, with Oxiris filters replaced every 24 hours per manufacturer guidelines.\n\nThe primary endpoints are changes in endothelial cell function assessed using induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) treated with patient plasma collected at three time points: CRRT initiation (baseline), day 3, and CRRT discontinuation. Endothelial function will be evaluated by tube formation assay (total tube length, branch points, mesh area) and reactive oxygen species (ROS) production. This iPSC-EC-based model provides a reproducible and standardized platform to directly assess the biological effects of Oxiris on vascular endothelial integrity under conditions mimicking the pathophysiological environment of septic AKI.\n\nSecondary endpoints include 90-day all-cause mortality, renal recovery (defined as dialysis independence at 90 days), changes in hemodynamic parameters (vasopressor requirements, mean arterial pressure), CRRT duration, and serial measurements of blood and urine biomarkers including NGAL, KIM-1, MCP-1, RANTES, and TGF-beta. These biomarkers reflect inflammatory burden, endothelial dysfunction, and renal tubular injury, providing a comprehensive assessment of the therapeutic effects of Oxiris beyond standard cytokine clearance.\n\nAs this is an exploratory study, all p-values will be interpreted descriptively and results will be used to generate hypotheses and inform the design of future confirmatory trials. The study aims to provide mechanistic insights into whether enhanced cytokine and endotoxin removal by Oxiris translates into measurable improvements in endothelial function and clinical renal outcomes.",[373],"Sepsis-associated AKI","2026-06-07",{"date":376,"type":44},"2026-06-11",{"date":378,"type":22},"2026-06-16",{"date":380,"type":22},"2029-03-09",{"name":50,"class":51},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100643743","effect-of-individualized-positive-end-expiratory-pressure-peep-in-patients-who-have-an-intrinsic-peep-during-one-lung-ventilation-100643743","NCT07638176","Effect of Individualized Positive End-expiratory Pressure (PEEP) in Patients Who Have an Intrinsic PEEP During One-lung Ventilation","Effects of Individualized Positive End-expiratory Pressure (PEEP) on Intrinsic PEEP and Stroke Volume During One-lung Ventilation: a Single-center, Randomized Crossover Study","Inclusion Criteria:\n\n* American Society of Anesthesiologists Physical Status I - III\n* The Eastern Cooperative Oncology Group Performance Status Grade 0 - 2\n* Lung resection surgery requiring one-lung ventilation for over 60 minutes\n* Indication of double-lumen endobronchial tube (female 35 Fr, male 37 Fr)\n* Patient who is diagnosed with intrinsic PEEP during one-lung ventilation\n\nExclusion Criteria:\n\n* Large bullae\n* Emergency surgery\n* Mechanical ventilation before surgery\n* Hemodynamic instability before surgery\n* Surgery requiring cardiopulmonary bypass\n* Pregnancy, breastfeeding patient\n* Patient's refusal to participate\n* No intrinsic PEEP during one-lung ventilation","100 Years",{"count":391,"type":22},48,[25],"This study investigates the effects of three extrinsic PEEP settings-5 cmH2O, 0 cmH2O, and an individualized PEEP (70% of the measured intrinsic PEEP)-on intrinsic PEEP and hemodynamic stability in patients with intrinsic PEEP undergoing lung resection surgery, using a randomized, crossover design.",[395,396],"Pulmonary Disease (COPD), Chronic Obstructive","Lung Resection Surgery","2026-06-04",{"date":355,"type":44},{"date":357,"type":22},{"date":401,"type":22},"2027-05-31",{"name":50,"class":51},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":410,"maxAge":154,"enrollmentInfo":411,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":429},"100641231","a-korean-point-prevalence-study-of-acute-rehabilitation-for-kids-in-the-picu-park-picu-100641231","NCT07629297","A Korean Point Prevalence Study of Acute Rehabilitation for Kids in the PICU (PARK-PICU)","Prevalence of Acute Rehabilitation for Kids in the Pediatric Intensive Care Unit","Inclusion Criteria:\n\n* Children and adolescents aged 18 years or younger who have been admitted to the pediatric intensive care unit (PICU) for at least 72 hours as of 9:00 AM on the predefined study date at participating hospitals.\n\nExclusion Criteria:\n\n* No exclusion criteria. All eligible patients meeting the inclusion criteria will be included to comprehensively assess the real-world prevalence of acute rehabilitation practices and associated barriers in pediatric intensive care units.","0 Days",{"count":412,"type":22},396,"This study investigates the prevalence of acute rehabilitation practices among children in pediatric intensive care units (PICUs).",[415],"Pediatric Intensive Care Units",[415,417,418,419,420,421],"Acute Rehabilitation","Rehabilitation Prevalence","Child","Critical Illness","Intensive Care Unit Acquired Weakness",{"date":423,"type":44},"2026-06-05",{"date":425,"type":22},"2026-05-28",{"date":427,"type":22},"2027-12-31",{"name":50,"class":51},13,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":52},"100640652","efficacy-of-early-rhythm-control-in-af-with-tr-patients-100640652","NCT07607093","Efficacy of Early Rhythm Control in AF With TR Patients","TRAF","Inclusion Criteria:\n\n* Patients with concomitant atrial fibrillation and tricuspid regurgitation.\n\nExclusion Criteria:\n\n* Patients with a history of valvular surgery\n* Patients with congenital heart disease\n* Patients with primary pulmonary hypertension\n* Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation\n* Patients diagnosed with TR only after the initiation of rhythm control therapy for AF",{"count":438,"type":22},5800,"Atrial fibrillation is frequently accompanied by tricuspid regurgitation and may contribute to right atrial and tricuspid annular remodeling, leading to progression of tricuspid regurgitation and adverse clinical outcomes. However, whether early rhythm control improves prognosis in patients with atrial fibrillation and tricuspid regurgitation remains unclear. This study will compare early rhythm control with usual care in these patients, using a composite outcome of cardiac death, heart failure admission, stroke, and tricuspid valve surgery.",[214,441],"Tricuspid Regurgitation (TR)",[443],"early rhythm control","2026-05-27",{"date":446,"type":44},"2026-05-29",{"date":448,"type":44},"2026-02-18",{"date":450,"type":22},"2027-02-28",{"name":50,"class":51},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":468,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":52},"100637792","pulsar-combined-with-immunotherapy-for-unresectable-locally-advanced-gastric-cancer-100637792","NCT07607119","PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer","A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer","Inclusion Criteria:\n\nAge 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS).\n\nUnresectable, locally advanced extent at initial staging (Para-aortic lymph node \\[PALN\\] and Supraclavicular lymph node \\[SCN\\] metastases are allowed).\n\nHas completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.\n\nPresence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.\n\nVoluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\nPregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness).\n\nInability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.",{"count":460,"type":22},53,[25],"The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.",[464,465,466,467],"Gastric Adenocarcinoma","Stomach Neoplasms","Locally Advanced Gastric Cancer","Unresectable Gastric Cancer",[469,470],"HER2-negative Stomach Cancer","Microsatellite Stable Gastric Cancer","2026-05-24",{"date":425,"type":44},{"date":474,"type":44},"2026-05-15",{"date":476,"type":22},"2030-04-30",{"name":50,"class":51},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":486,"conditions":487,"keywords":491,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":498,"locationsCount":52},"100640243","dumping-syndrome-after-esophagectomy-100640243","NCT07605481","Dumping Syndrome After Esophagectomy","Prospective Observational Study on the Utility of Continuous Glucose Monitoring for the Diagnosis of Dumping Syndrome After Esophagectomy","Inclusion Criteria:\n\n-1. aged 18 or older. 2. people who underwent esophagectomy and gastric tube reconstruction for esophageal cancer.\n\n3\\. Sigstad score of 7 or higher.\n\nExclusion Criteria:\n\n* 1\\. Diabetes with autonomic neuropathy. 2. Inability to complete the diagnostic procedure (e.g., cognitive decline). 3. Refusal to participate.",{"count":291,"type":22},"Background:\n\nDumping syndrome is a common complication for patients who have undergone surgery for esophageal cancer. It occurs when food moves too quickly from the stomach (or the reconstructed gastric tube) into the small intestine. This rapid movement causes various symptoms such as bloating, abdominal pain, dizziness, rapid heartbeat, and sweating. Sometimes, it leads to \"late dumping,\" where blood sugar levels drop significantly, causing tremors, cold sweats, and fatigue. Currently, there is no standardized tool to easily diagnose this condition after esophagectomy.\n\nPurpose of the Study:\n\nThe objective of this study is to evaluate the effectiveness of Continuous Glucose Monitoring (CGM) in diagnosing dumping syndrome. CGM is a small, wearable sensor that tracks glucose levels in real-time. The investigators aim to determine whether CGM can serve as a valuable tool for the early detection of dumping syndrome in patients who have undergone esophagectomy.",[488,489,490],"Esophagectomy","Dumping Syndrome","Continous Glucose Measurement",[492,493],"esophagectomy","dumping syndrome","2026-05-21",{"date":94,"type":44},{"date":310,"type":22},{"date":259,"type":22},{"name":50,"class":51},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":506,"targetDuration":508,"studyType":133,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":52},"100635933","imaging-based-prediction-of-eligibility-for-chemoimmunotherapy-in-resectable-nsclc-iprecise-100635933","NCT07559123","Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE","iPRECISE","Inclusion Criteria:\n\n* Age: 18 years or older.\n* Diagnosis: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).\n* Staging: Resectable NSCLC of stage IIIA or lower.\n* Treatment Plan: Planned to receive neoadjuvant chemoimmunotherapy before surgery according to standard clinical practice.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Informed Consent: Able and willing to provide written informed consent after receiving a detailed explanation of the study.\n\nExclusion Criteria:\n\n* No Measurable Lesion: Participants must have at least one measurable lesion (\\>= 10 mm on spiral\u002Fmultidetector computed tomography).\n* Prior Malignancy: History of another malignancy within 5 years before enrollment (excluding adequately treated basal cell skin carcinoma or cervical carcinoma in situ).\n* Neurological\u002FPsychiatric Conditions: History of clinically significant uncontrolled seizures, CNS disease, or psychiatric disorders that may interfere with study participation or consent.\n* Contrast Allergy: History of severe allergic reaction to iodinated CT contrast media.\n* Renal Impairment: Acute renal failure or moderate to severe renal impairment (CrCl \\\u003C 45 mL\u002Fmin\u002F1.73 m² or serum creatinine \\> 1.5x upper limit of normal).\n* Recent Surgery: Major surgery within 4 weeks of enrollment or incomplete recovery from major surgery.\n* Pregnancy\u002FNursing: Currently pregnant or breastfeeding; women of childbearing potential without a negative baseline pregnancy test.\n* Contraception: Men or women of childbearing potential unwilling to use appropriate contraception during the study.",{"count":507,"type":22},150,"3 Years","This study is for adults with resectable non-small cell lung cancer who are scheduled to receive neoadjuvant chemoimmunotherapy before surgery.\n\nNeoadjuvant chemoimmunotherapy can help shrink lung cancer before surgery and may improve treatment outcomes. However, not all patients benefit from this treatment in the same way, and it can sometimes cause side effects, such as immune-related pneumonitis. At present, it is still difficult to predict before or during treatment which patients will have a strong response.\n\nThe purpose of this study is to find imaging features on chest computed tomography scans that may help predict how well a patient's cancer responds to neoadjuvant chemoimmunotherapy. The study will compare computed tomography findings before treatment and before surgery with pathologic findings from surgery, including pathologic complete response and major pathologic response. The study will also evaluate whether computed tomography-based imaging features are associated with treatment-related side effects and long-term outcomes such as disease progression and survival.\n\nThis is an observational study. The investigators will not assign participants to a specific cancer treatment. Participants will receive neoadjuvant chemoimmunotherapy and surgery according to standard clinical practice. Chest computed tomography scans will be obtained before treatment and before surgery as part of the study protocol. These computed tomography images will also be reconstructed using a high-resolution deep learning-based computed tomography reconstruction technique to explore whether this approach can improve the development of imaging biomarkers.\n\nThe results of this study may help develop a noninvasive imaging-based model to identify patients who are more likely to benefit from neoadjuvant chemoimmunotherapy and to better guide treatment planning for resectable non-small cell lung cancer.",[511,512,513],"NSCLC","Neoadjuvant Chemoimmunotherapy","CT","2026-05-05",{"date":516,"type":44},"2026-05-08",{"date":518,"type":44},"2026-02-01",{"date":144,"type":22},{"name":50,"class":51},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":52},"100636578","early-detection-of-concealed-cardiac-amyloidosis-using-ai-ecg-and-ct-derived-extracellular-volume-in-patients-with-atrial-fibrillation-100636578","NCT07567508","Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation","SEARCH-AF","Inclusion Criteria:\n\n* Adults aged 19 or older who have provided voluntary written informed consent.\n* Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms\u002Fsigns.\n* Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.\n\nExclusion Criteria:\n\n* Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).\n* Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.\n* Patients deemed inappropriate for participation by the investigator.",{"count":529,"type":22},500,[25],"This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with \"red-flag\" indicators.\n\nParticipants are randomized 1:1 into either an early screening or usual care group.\n\n* Early screening group : AI- ECG and\u002For CT-ECV analysis + AF treatment\n* Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.",[214,533],"Cardiac Amyloidosis",[535,536,537,66],"AI-ECG","Amyloidosis","Cardiac amyloidosis","2026-04-28",{"date":514,"type":44},{"date":541,"type":22},"2026-05",{"date":96,"type":22},{"name":50,"class":51},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":559,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":52},"100636243","impact-of-optimized-pacing-strategies-on-clinical-and-hemodynamic-outcomes-in-heart-failure-patients-with-pacemaker-100636243","NCT07563153","Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker","Clinical and Hemodynamic Outcomes of OPTimized PACing StratEgies in Heart Failure Patients With Pacing Indications: Randomized-Controlled Trial (OPTPACE-HF)","OPTPACE-HF","Inclusion Criteria:\n\n* Patients with symptomatic bradycardia who meet the indication for permanent pacemaker implantation and fulfill one of the following conditions:\n\n  1. Sick sinus syndrome with or without impaired atrioventricular conduction\n  2. Persistent or permanent atrial fibrillation with slow ventricular response\n  3. Chronotropic incompetence\n* Patients diagnosed with heart failure with left ventricular ejection fraction ≥ 50% on transthoracic echocardiography with at least one of the following:\n* H2FPEF score ≥ 6 or HFA-PEFF score ≥ 5\n* N-terminal pro-B-type natriuretic peptide ≥ 300 pg\u002FmL (sinus rhythm) or ≥ 600 pg\u002FmL (atrial fibrillation)\n* Prior hospitalization for heart failure or documented use of loop diuretics for heart failure symptoms\n\nExclusion Criteria:\n\n* Patients expected to have a ventricular pacing burden ≥ 20% without sufficient capture of cardiac physiologic pacing, which includes biventricular pacing, His bundle pacing, and left bundle branch area pacing.\n\n(Sufficient cardiac physiologic pacing is defined as a paced QRS duration ≤ 140 ms.)\n\n* Patients not expected to achieve sufficient pacing dependency, defined as:\n\n  1. In sinus rhythm: baseline atrial rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n  2. In atrial fibrillation\u002Fflutter: baseline ventricular rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n* Patients with contraindications to permanent pacemaker implantation\n* Patients with moderate or greater valvular stenosis or regurgitation.\n* Patients with dyspnea not attributable to heart failure, due to uncontrolled comorbid conditions\n* Pregnant or breastfeeding women.\n* Patients who have refused active treatment.",{"count":553,"type":22},106,[25],"This study aims to evaluate the clinical impact of an optimized pacing strategy in patients with heart failure.\n\n* Intervention: Adjustment of the pacemaker lower rate limit to an individualized, hemodynamically optimized heart rate.\n* Primary Endpoint: Heart failure symptoms, assessed by the Kansas City Cardiomyopathy Questionnaire score.\n* Hypothesis: In patients with heart failure requiring permanent pacing, an optimized pacing strategy will lead to a significant improvement in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire score) at 12 months compared with the conventional pacing strategy.",[557,558],"Heart Failure","Bradycardia",[560,561,562,563],"Heart failure","bradycardia","CIED","lower rate",{"date":565,"type":44},"2026-05-01",{"date":567,"type":44},"2025-12-18",{"date":259,"type":22},{"name":50,"class":51},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":4},"100616075","phase-2-t-cell-inflamed-gene-expression-profiling-score-guided-anti-pd-1-therapy-tislelizumab-monotherapy-for-refractory-solid-cancer-patients-unexposed-to-immunotherapy-100616075","NCT07300891","T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy","Inclusion Criteria:\n\n1. Patients aged ≥ 20 years at the time of informed consent.\n2. Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.\n3. Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.\n4. ECOG Performance Status Score 0 or 1.\n5. Patients with a life expectancy of at least 3 months.\n6. Patients with adequate hematological and biological function as indicated by the following screening laboratory values:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL\n   * Platelets ≥ 75×109\u002FL\n   * Hemoglobin ≥ 9g\u002FdL or ≥ 5.6 mmol\u002FL (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)\n   * Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL\u002Fmin by Cockcroft-Gault formula\n   * Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be \\\u003C 3×ULN for patients with Gilbert's syndrome)\n   * Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases\n\nExclusion Criteria:\n\n1. Patients aged ≥ 20 years at the time of informed consent.\n2. Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.\n3. Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.\n4. ECOG Performance Status Score 0 or 1.\n5. Patients with a life expectancy of at least 3 months.\n6. Patients with adequate hematological and biological function as indicated by the following screening laboratory values:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL\n   * Platelets ≥ 75×109\u002FL\n   * Hemoglobin ≥ 9g\u002FdL or ≥ 5.6 mmol\u002FL (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)\n   * Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL\u002Fmin by Cockcroft-Gault formula\n   * Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be \\\u003C 3×ULN for patients with Gilbert's syndrome)\n   * Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases\n\nKey exclusion criteria Patients who meet any of the following criteria at the time of assessment will be excluded.\n\n1. Patients with solid tumors from multiple primary origin (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years).\n2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.\n3. Patients are expected to require any other form of systemic or localized antineoplastic therapy while on trial (including radiation therapy, and\u002For surgical resection).\n4. Patients who have previously received treatment with PD-1\u002FPD-L1 inhibitor or CTLA-4 inhibitor e.g. pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, tislelizumab, dostarlimab, spartalizumab tremelimumab or ipilimumab\n5. Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for ≥ 4 weeks before first dose of study drug.\n6. Patients have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study in terms of efficacy and safety, interfere with the subject's participation for the full duration of the trial, or are not in the best interest of the subject to participate, in the opinion of the treating investigator.\n7. Women who are pregnant or breastfeeding, or possibly pregnant.\n8. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before first dose of study drug.",{"count":577,"type":22},72,[87],"This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score ≥ 0.857, who have not been previously exposed to immunotherapy.\n\nAll patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tissue slide collected within 2 years from the first dose of study drug must be provided.\n\nThis study will include a Screening Period, a Treatment Period, and a Follow-Up Period. All patients will complete up to 28 days of screening. During the Treatment Period, patients will receive tislelizumab 200 mg fixed dose once every 3 weeks by intravenous (IV) administration until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.\n\nAfter treatment discontinuation, patients will be follow-up for disease progression and survival status until death, withdrawal of consent, or study closure, whichever occurs first.\n\nThe end of study will be the timepoint when the final data for the study were collected. Additionally, the Investigator Sponsor has the right to terminate this study at any time.",[581],"Refractory Solid Cancer Patients Unexposed to Immunotherapy","2026-04-26",{"date":538,"type":44},{"date":585,"type":22},"2026-08",{"date":587,"type":22},"2028-01-31",{"name":50,"class":51},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":596,"sex":17,"minAge":597,"maxAge":347,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":52},"100479859","phase-2-osimertinib-to-suppress-the-progression-of-remaining-ggn-for-egfr-mutation-positive-stage-ib-iiia-lung-adenocarcinoma-100479859","NCT05528458","Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Adult male or female patients, aged from 30 to 75 years\n3. Pathologic proven lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with well-defined margin, mean density above -500 HU and greater than 7.5 mm in its maximum diameter\n4. The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.\n5. WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks\n6. Complete surgical resection of the primary NSCLC is mandatory.\n7. Uneventful recovery from curative-intent lung cancer surgery\n\nFor assignment in the control arm, subjects should be classified post-operatively as Stage IA on the basis of pathologic criteria (the 8th edition of TNM staging system for lung cancer).\n\nFor assignment in the treatment arm, subjects should fulfil the following criteria in addition to the above criteria.\n\n* Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic cirteria (the 8th edition of TNM staging system for lung cancer)\n* Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n\nFurther information in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n\n\\- Male subjects should be willing to use barrier contraception during the study and for 4 months after last dose of osimertinib\n\nExclusion Criteria:\n\n1. Regression of synchronous GGN after adjuvant chemotherapy prior to osimertinib\n2. Past history of postoperative ALI\u002FARDS or pneumonia during recovery period\n3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix C). All patients must try to avoid concomitant use of any medications, herbal supplements and\u002For ingestion of foods with known inducer effects on CYP3A4.\n4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n6. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value. Whenever QTc, is mentioned in this document, this refers to correction e made by Fridericia formula (QTcF),\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\u002Fplasma potassium \\\u003C lower limit of normal (LLN); Serum\u002Fplasma magnesium \\\u003C LLN; Serum\u002Fplasma calcium \\\u003C LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n8. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n   * Absolute neutrophil count \\\u003C1.5 x 109\u002FL;\n   * Platelet count \\\u003C100 x 109\u002FL;\n   * Haemoglobin \\\u003C90 g\u002FL;\n   * Alanine aminotransferase \\>2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n   * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\\u003C50 mL\u002Fmin \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n9. Women who are breast-feeding\n10. Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n11. Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site).\n12. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.",true,"30 Years",{"count":599,"type":22},59,[87],"This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.",[603],"Lung Adenocarcinoma",{"date":538,"type":44},{"date":606,"type":44},"2022-09-11",{"date":608,"type":22},"2027-12-01",{"name":50,"class":51},""]